University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Items where Author is "Tayebi, M"

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 28.

Article

Rusbridge, Clare, Salguero Bodes, Francisco, David, Monique A., Faller, Kiterie, Bras, Jose T., Guerreiro, Rita, Richard-Loendt, Angela C., Grainger, Duncan, Head, Elizabeth, Brandner, Sebastian G., Summers, Brian, Hardy, John and Tayebi, Mourad (2018) An aged canid with behavioural deficits exhibits blood and cerebrospinal fluid amyloid beta oligomers Frontiers in Aging Neuroscience.

David, MA, Jones, DR and Tayebi, M (2014) Potential candidate camelid antibodies for the treatment of protein-misfolding diseases JOURNAL OF NEUROIMMUNOLOGY, 272 (1-2). pp. 76-85.

Tayebi, M, Jones, DR, Taylor, WA, Stileman, BF, Chapman, C, Zhao, D and David, M (2011) PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers. PLoS One, 6 (5).

Tayebi, M, David, M, Bate, C, Jones, D, Taylor, W, Morton, R, Pollard, J and Hawke, S (2010) Epitope-specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis. J Gen Virol, 91 (Pt 12). pp. 3105-3115.

Bate, C, Tayebi, M and Williams, A (2010) Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation. J Biol Chem, 285 (29). pp. 22017-22026.

Bate, C, Tayebi, M and Williams, A (2010) A glycosylphosphatidylinositol analogue reduced prion-derived peptide mediated activation of cytoplasmic phospholipase A2, synapse degeneration and neuronal death. Neuropharmacology, 59 (1-2). pp. 93-99.

Bate, C, Tayebi, M and Williams, A (2010) The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication. Biochem J, 428 (1). pp. 95-101.

Bate, C, Tayebi, M, Salmona, M, Diomede, L and Williams, A (2010) Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox Res, 17 (3). pp. 203-214.

Bate, C, Tayebi, M and Williams, A (2010) Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener, 5.

Jones, DR, Taylor, WA, Bate, C, David, M and Tayebi, M (2010) A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS One, 5 (3).

Tayebi, M, Collinge, J and Hawke, S (2009) Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol, 90 (Pt 3). pp. 777-782.

Bate, C, Tayebi, M, Diomede, L, Salmona, M and Williams, A (2009) Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One, 4 (12).

Bate, C, Tayebi, M and Williams, A (2008) Cholesterol esterification reduces the neurotoxicity of prions. Neuropharmacology, 54 (8). pp. 1247-1253.

Bate, C, Tayebi, M, Diomede, L, Salmona, M and Williams, A (2008) Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol, 6.

Bate, C, Tayebi, M and Williams, A (2008) Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegener, 3.

Bate, C, Tayebi, M and Williams, A (2008) Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol, 6.

Tayebi, M, Bate, C, Hawke, S and Williams, A (2007) A role for B lymphocytes in anti-infective prion therapies? Expert Rev Anti Infect Ther, 5 (4). pp. 631-638.

Tayebi, M and Hawke, S (2006) Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases. Immunol Lett, 105 (2). pp. 123-126.

Khalili-Shirazi, A, Quarantino, S, Londei, M, Summers, L, Tayebi, M, Clarke, AR, Hawke, SH, Jackson, GS and Collinge, J (2005) Protein conformation significantly influences immune responses to prion protein. J Immunol, 174 (6), 15749856. pp. 3256-3263.

Beringue, V, Vilette, D, Mallinson, G, Archer, F, Kaisar, M, Tayebi, M, Jackson, GS, Clarke, AR, Laude, H, Collinge, J and Hawke, S (2004) PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem, 279 (38). pp. 39671-39676.

Tayebi, M, Enever, P, Sattar, Z, Collinge, J and Hawke, S (2004) Disease-associated prion protein elicits immunoglobulin M responses in vivo. Mol Med, 10 (7-12). pp. 104-111.

Beringue, V, Mallinson, G, Kaisar, M, Tayebi, M, Sattar, Z, Jackson, G, Anstee, D, Collinge, J and Hawke, S (2003) Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain, 126 (Pt 9). pp. 2065-2073.

White, AR, Enever, P, Tayebi, M, Mushens, R, Linehan, J, Brandner, S, Anstee, D, Collinge, J and Hawke, S (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 422 (6927). pp. 80-83.

Conference or Workshop Item

Tayebi, M, Vendruscolo, M and David, MA (2011) Anti-oligomer monoclonal antibodies reveal that protein aggregation modulates generalized physiological and pathological disturbances In: PrioNet & Neuroprion, 2011-05-16 - 2011-05-19, Monteal Canada.

Tayebi, M and David, MA Canine spongiform encephalopathy-A new form of animal prion disease In: NEUROPRION, 2012-05-09 - 2012-05-12, AMSTERDAM, THE NETHERLANDS.

Tayebi, M, Sattar, Z, Kaisar, M, Khallili-Shirazi, A, Mallinson, G, Jackson, GS, Collinge, J and Hawke, S PrP conformation and genotype profoundly influence anti-PrP antibody specificity In: Immunology, 2011 - ?, UK.

Patent

UNSPECIFIED ANTIBODIES SPECIFIC FOR MISFOLDED PROTEINS AND METHODS FOR THEIR PRODUCTION WO Patent 2,010,015,834.

UNSPECIFIED CARRIER WO Patent 2,010,038,035.

This list was generated on Sun Jan 21 05:12:52 2018 UTC.

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800